Baird raised the firm’s price target on Insulet (PODD) to $360 from $350 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which reaccelerating growth and a growing competitive advantage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $350 from $330 at RBC Capital
- Insulet price target raised to $353 from $331 at Canaccord
- Insulet Corporation Reports Strong Q2 2025 Growth
- Insulet’s Earnings Call Highlights Robust Growth and Optimism
- Insulet’s Strong Financial Performance and Optimistic Outlook Justify Buy Rating